2090: Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)

Alan Cheng¹, Vibeke Strand², Jiandong Su³, Nicole Anderson³, Lee S Simon⁴ and Zahi Touma³, ¹Michael G. DeGroote School of Medicine, McMaster University, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ²Stanford University School of Medicine, Stanford, CA, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴SDG LLC, West Newton, MA

Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a novel valid index able to measure disease activity while accounting for prednisone usage. Previous studies examining disease activity and Health-related quality of life (HRQoL) have been inconsistent, with most finding no association between the two. Given that SLE patients report lower HRQoL compared to the general population, establishing a better understanding between disease activity and its impact on HRQoL may improve patients' health outcomes.

This study had 2 aims:

1) Ascertain the association of the novel index, SLEDAI-2KG with the 36-Item Short Form Survey (SF-36), and
2) Compare the performances of the SLEDAI-2K and SLEDAI-2KG in determining poor HRQoL based on normative Canadian population data.

Methods: This is a single centre cross-sectional retrospective analysis of 1357 patients treated from 1994 to 2020. Data from SLEDAI-2K, SLEDAI-2KG and SF-36 at the first visit in the cohort were analysed. Descriptive statistics were used to describe patients' baseline characteristics.

Aim 1: We hypothesised that SLEDAI-2K and SLEDAI-2KG would have none to low correlations with SF-36 domains but that SLEDAI-2KG would show better correlations. Spearman correlations were determined between disease activity indices and SF-36 domains.

Aim 2: Age and gender (A/G) matched SF-36 scores based on Canadian population norms were determined and HRQOL was then categorized as below or equal to or above Canadian norms. Univariate logistic regressions were performed using either SLEDAI-2K or SLEDAI-2KG as the sole independent variable to evaluate the association with normative scores.

Results: 1357 SLE patients (88.5% female) were included in the study. Mean age and duration of SLE at the 1st visit were 38.0 ± 13.6 and 8.5 ± 5.2 years respectively. 854 (62.9%) patients were treated with prednisone at mean doses of 12.0 ± 11.6 mg/day (Table 1). SLEDAI-2KG scores were in general 2 points higher than SLEDAI-2K scores (6.5 ± 5.9 and 4.5 ± 4.7 respectively).

There were weak negative correlations (r < 0.3) with both SLEDAI-2K and SLEDAI-2KG and the 8 SF-36 domain and physical (PCS) and mental (MCS) component summary scores, ranging from -0.06 to -0.12 and -0.07 to -0.20 respectively. Correlation coefficients of SLEDAI-2KG with SF-36 were approximately double those of SLEDAI-2K but remained < 0.3.

When dichotomizing SF-36 scores based on Canadian A/G matched norms, the majority of patients reported scores less than (54.0-88.0%) normative values across all SF-36 domains, PCS and MCS, with exception of the Role Emotional domain (43.9%) (Table 2).

In univariate analyses, an increase of 1 in the SLEDAI-2KG score was associated with higher odds of SF-36 scores less than Canadian norms compared with SLEDAI-2K (14-47% vs. 10-30% respectively) (Table 3).

Conclusion: Both SLEDAI-2K and SLEDAI-2KG scores weakly correlated with SF-36. SLEDAI-2KG, compared with SLEDAI-2K, was more likely to identify SLE patients with poorer HRQoL across all SF-36 domains. These results might serve as a more comprehensive guide for determining disease prognosis and treatment decisions to improve HRQoL in SLE.
Table 1: Spearman correlations between two SLEDAI total scores and eight SF36 domain and two component scores

Table 2: Percentage of patients reporting SF-36 domain scores lower than Canadian age/gender matched norms

Table 3: Univariate Logistic regression to identify patients lower than Canadian norm by gender/age standardized for SF-36 domains
Disclosures: A. Cheng, None; V. Strand, AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb(BMS), Boehringer-Ingelheim, Chemocentryx, Celltrion, Genentech/Roche, Gilead, GlaxoSmithKlein(GSK), Inmedix, Janssen, Kiniksa, Merck/MSD, Novartis, Pfizer, Regeneron Pharmaceuticals, Rheos, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Spherix, Aria, Bioventus, Blackrock, Equilium, Glenmark, Horizon, Kypha, Lilly, MiMedx, Sorrento, Tonix, Priovant; J. Su, None; N. Anderson, None; L. Simon, None; Z. Touma, None.